Lovenox

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

29 API Suppliers, 14 USDMF, 3 CEP/COS, 1 EU WC, 3 KDMF, 6 NDC API, 16 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

284 FDF Dossiers, 62 FDA Orange Book, 78 Europe, 37 Canada, 26 Australia, 14 South Africa, 67 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - 100MG/ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 120MG/0.8ML (150MG/ML), INJECTABLE;SUBCUTANEOUS - 150MG/ML (150MG/ML), INJECTABLE;INTRAVENOUS, SUBCUTANEOUS - 300MG/3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 30MG/0.3ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 40MG/0.4ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 60MG/0.6ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 80MG/0.8ML (100MG/ML), INJECTABLE;SUBCUTANEOUS - 90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**